Icon Wealth Advisors LLC Purchases 75,569 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Icon Wealth Advisors LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18,342.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 75,981 shares of the biopharmaceutical company’s stock after acquiring an additional 75,569 shares during the quarter. Regeneron Pharmaceuticals accounts for 3.0% of Icon Wealth Advisors LLC’s holdings, making the stock its 5th biggest position. Icon Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $79,874,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in REGN. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $26,000. Sachetta LLC raised its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth about $28,000. Finally, Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ:REGN opened at $745.48 on Friday. The firm has a market cap of $81.92 billion, a P/E ratio of 18.45, a P/E/G ratio of 2.81 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20. The business has a fifty day simple moving average of $953.38 and a 200 day simple moving average of $1,028.16. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Oppenheimer reduced their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.